Allarity Therapeutics, Inc. ALLR 深 沪
已收盘 04-02 16:00:00 美东时间
1.16
+0.030
+2.65%
华盛通- 最 高1.19
- 今 开1.13
- 成交量 5.51万股
- 最 低 1.12
- 昨 收 1.13
- 总市值 1835.00万
- 52周最高 2.35
- 市盈率 静 --
- 换手率 0.35%
- 52周最低 0.6585
- 委 比 -33.77%
- 总股本 1581.90万
- 历史最高 15288000.00
- 量 比 0.54
- 振 幅 6.19%
- 历史最低 0.6138
- 每 手 1
- 风险率 0.26%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多Allarity Therapeutics Q4 EPS $(0.21), Inline, Sales $320.000K
Allarity Therapeutics (NASDAQ:ALLR) reported quarterly losses of $(0.21) per share which met the analyst consensus estimate. This is a 87.79 percent increase over losses of $(1.72) per share from the same period last
03-31 22:24
Allarity Therapeutics Closes $20M Non-Convertible Debt Funding With Streeterville Capital; Expects Cash Runway To Support Operations Through Mid-2028
Allarity Therapeutics, Inc. ("Allarity" or the "Company") (NASDAQ: ALLR), a Phase 2 clinical-stage pharmaceutical company dedicated to developing stenoparib (2X-121)—a differentiated, dual PARP and WNT pathway
03-06 21:11
Allarity Therapeutics Starts Enrollment For Phase 2 Trial To Developing Senoparib
This is the first trial combining Allarity's stenoparib with another anti-cancer agent Stenoparib's favorable safety profile supports potential for use in combination regimens Trial is fully funded by the U.S.
02-03 21:09
Allarity Therapeutics Files Prospectus To Offer Up To $50M In Various Securities
Allarity Therapeutics, Inc.$50,000,000Common StockPreferred StockDebt SecuritiesWarrantsRightsUnits We may from time to time, in one or more offerings, offer and sell up to $50,000,000 in the aggregate of the
2025-12-03 22:14
Allarity Therapeutics Q3 EPS $(0.19) Beats $(0.21) Estimate
Allarity Therapeutics (NASDAQ:ALLR) reported quarterly losses of $(0.19) per share which beat the analyst consensus estimate of $(0.21) by 9.52 percent. This is a 97.54 percent increase over losses of $(7.71) per share
2025-11-14 22:11
美股大行评级 | 潜在涨幅485.44%！Allarity Therapeutics获机构升目标价至9.25美元，维持"买入"评级
今日重点评级关注：Ascendiant Capital：维持Allarity Therapeutics"买入"评级，目标价从9美元升至9.25美元；JMP证券：维持Crinetics Pharmaceuticals"跑赢大市"评级，目标价从86美元升至143美元
2025-09-29 09:15
Ascendiant Capital Maintains Buy on Allarity Therapeutics, Raises Price Target to $9.25
Ascendiant Capital analyst Edward Woo maintains Allarity Therapeutics (NASDAQ: ALLR) with a Buy and raises the price target from $9 to $9.25.
2025-09-26 17:55
Allarity Therapeutics CEO to Present at Biomarkers & Precision Medicine 2025
Allarity Therapeutics' CEO, Thomas Jensen, will present at the Biomarkers & Precision Medicine 2025 conference in London, discussing a gene expression biomarker for stenoparib response. He will also be interviewed by Oxford Global. Stenoparib, a dual PARP1/2 and tankyrase inhibitor, targets ovarian cancer. Allarity's DRP® companion diagnostic platform selects patients likely to benefit from stenoparib. The company focuses on personalized cancer t...
2025-09-17 12:00
12 Health Care Stocks Moving In Tuesday's Pre-Market Session
Gainers Invivyd (NASDAQ:IVVD) stock increased by 132.3% to $1.3 during Tuesday...
2025-08-26 20:09
